PUBLISHER: 360iResearch | PRODUCT CODE: 1676914
PUBLISHER: 360iResearch | PRODUCT CODE: 1676914
IgA Nephropathy Market by Drug Class, Treatment, Patient Type, End User, Distribution Channel - Global Forecast 2025-2030
The IgA Nephropathy Market was valued at USD 149.72 million in 2024 and is projected to grow to USD 158.57 million in 2025, with a CAGR of 6.10%, reaching USD 213.67 million by 2030.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2024] | USD 149.72 million |
| Estimated Year [2025] | USD 158.57 million |
| Forecast Year [2030] | USD 213.67 million |
| CAGR (%) | 6.10% |
In recent years, the landscape surrounding IgA Nephropathy has evolved dramatically. This report provides an in-depth analysis of market trends, developments, and emerging opportunities that are reshaping how stakeholders approach the management and treatment of this complex condition. IgA Nephropathy, a primary form of glomerulonephritis, has garnered extensive research focus due to its dire impact on kidney functions and the associated long-term health implications.
The content herein is designed to offer both a macro and micro perspective-detailing the interplay of clinical innovation, patient demographics, and regional variations that collectively drive market dynamics. By examining these facets, readers can develop a comprehensive understanding of the forces steering the treatment paradigm. Our investigation delves into critical aspects such as drug classes, treatment modalities, patient types, end-user settings, and distribution channels, offering a multi-layered story that bridges the gap between clinical research and market deployment.
From the challenges of early diagnosis and disease variability to the advances in immunosuppressive therapies and precision medicine, this introductory section sets the stage for a detailed exploration of the transformative shifts affecting the IgA Nephropathy market globally. As various sectors evolve, the report underscores the role of robust research and strategic investments in redefining patient care pathways and enhancing overall outcomes.
Transformative Shifts in the IgA Nephropathy Market Landscape
Over the past decade, the IgA Nephropathy market has experienced significant transformative shifts, propelled by a constellation of technological, clinical, and regulatory changes. Contemporary research has ushered in newer molecular insights and targeted therapeutic developments, reshaping not only diagnostic approaches but also the treatment strategies implemented worldwide.
Innovations in biotechnology and pharmaceutical sciences have led to the development of advanced drug classes and targeted therapies. These advancements enable improved management of disease progression while mitigating the side effects traditionally associated with immunosuppressive treatments. The emergence of novel monoclonal antibodies, refined corticosteroid regimens, and the integration of precision medicine have redefined therapeutic approaches. This evolution is closely tied to a deeper understanding of underlying immunological mechanisms, which has encouraged broader investment in early-phase clinical trials that show promising results.
Furthermore, the regulatory environment has adapted in step with these clinical advancements. Enhanced collaboration between regulatory bodies and research institutions has streamlined the path from development to market approval. As clinical trials become more robust and data-driven, there is an increasing emphasis on real-world evidence, which serves as a vital contributor to post-market surveillance and therapy optimization. These factors collectively amplify the momentum in treatment strategies, ensuring that therapies are not only effective but also accessible.
Market players are leveraging cross-sector partnerships to design holistic care models that integrate both innovative treatments and established modalities. As a result, the trajectory of IgA Nephropathy treatment has shifted from traditional management to a dynamic, patient-centric approach that continuously adapts to emerging scientific evidence and patient needs.
Key Segmentation Insights into the IgA Nephropathy Market
The segmentation of the IgA Nephropathy market is instrumental in comprehending the nuanced drivers of market growth and therapy optimization. When evaluated on the basis of drug class, the market extends across categories including ACE inhibitors, angiotensin receptor blockers, corticosteroids, immunosuppressants, and monoclonal antibodies. These drug classes reflect the evolution of pharmacotherapy from well-established agents to contemporary, targeted biological interventions that offer improved specificity and reduced systemic side effects.
In terms of treatment modes, the research encapsulates modalities such as dialysis, immunosuppressive therapy, kidney transplant, and plasmapheresis. Each of these treatments plays a pivotal role in addressing different stages and severities of the disease, thereby ensuring that patient care is appropriately tailored based on clinical presentation and progression. Analyzing the intricacies of treatment options provides clarity on the advantages and limitations inherent in each modality.
Furthermore, segmentation by patient type distinguishes between adult and pediatric patients, a categorization that is critical given the differing physiological responses and prognostic outcomes observed across age groups. Tailored treatment protocols in these divergent populations underscore the need for personalized medicine and targeted interventions.
The market is also stratified by the end user, spanning home healthcare, hospitals, research institutes, and specialty clinics. This classification provides essential insight into the spread of healthcare delivery settings and the growing demand for specialized care facilities that can manage complex disease presentations effectively. Finally, the segmentation based on the distribution channel, which highlights hospital pharmacies, online pharmacies, and retail pharmacies, sheds light on the evolving dynamics of pharmaceutical logistics and market reach.
These segmentation insights offer a detailed panorama that is essential for stakeholders seeking to harness opportunities in both emerging and mature segments of the IgA Nephropathy market. By exploring each facet of segmentation, industry participants can better strategize resource allocation, align product development with patient needs, and optimize market penetration across various channels.
Based on Drug Class, market is studied across ACE Inhibitors, Angiotensin Receptor Blockers, Corticosteroids, Immunosuppressants, and Monoclonal Antibodies.
Based on Treatment, market is studied across Dialysis, Immunosuppressive Therapy, Kidney Transplant, and Plasmapheresis.
Based on Patient Type, market is studied across Adults and Pediatric Patients.
Based on End User, market is studied across Home Healthcare, Hospitals, Research Institutes, and Specialty Clinics.
Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
Regional Dynamics Shaping the IgA Nephropathy Market
Regional insights form a critical element of the comprehensive market analysis for IgA Nephropathy. Each major region exhibits unique characteristics that contribute to the distinctive market dynamics observed globally. The Americas continue to be a stronghold for innovative therapies and robust healthcare infrastructure. Investment in research coupled with advanced technological adoption has paved the way for integrated care pathways that significantly enhance treatment outcomes.
In the Europe, Middle East & Africa region, there has been a concerted effort to balance traditional care approaches with emerging therapeutic innovations. Policy initiatives and regulatory reforms in this region have fostered an environment conducive to clinical trial participation and accelerated drug approval processes. The interplay of well-established healthcare systems and burgeoning biotech sectors continues to influence the deployment of modern treatments, making this region a key arena for market expansion.
In Asia-Pacific, rapid economic development and increased government incentives in healthcare research have spurred significant market growth. The region's focus on improving access to healthcare, coupled with an increasing prevalence of chronic kidney diseases, has provided a strong impetus for investment in IgA Nephropathy therapies. Innovative treatment protocols are now being integrated alongside traditional practices to meet the rising demand for specialized care. This dynamic backdrop not only enhances patient outcomes but also provides substantial opportunities for market entrants aiming to capture significant shares in evolving healthcare ecosystems.
These regional variations underscore the importance of tailoring strategic approaches to the specificities of each market. Understanding these dynamics is essential for organizations seeking to establish or expand their presence in the global IgA Nephropathy market.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Leading Companies Reshaping the IgA Nephropathy Landscape
The competitive landscape within the IgA Nephropathy market is marked by a collection of leading pharmaceutical and biotechnology companies that are at the forefront of therapeutic innovation. Key players such as Alexion Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. have been instrumental in developing breakthrough therapies that promise improved patient outcomes. Among others, Apellis Pharmaceuticals Inc., AstraZeneca PLC, and Biogen Inc. are also making significant strides with their investments in research and development.
Further, firms like Calliditas Therapeutics AB, ChemoCentryx, Inc. by Amgen, and Eledon Pharmaceuticals Inc. have demonstrated a robust commitment to addressing unmet clinical needs through targeted therapeutic solutions. The industry's trajectory has also been shaped by the activities of F. Hoffmann-La Roche Ltd and Ionis Pharmaceuticals Inc., which have effectively harnessed innovative technologies to refine patient care models. Other notable competitors such as Keymed Biosciences Inc., Merck KGaA, and Novartis AG continue to influence market trends through strategic partnerships and sustained research investments.
The landscape is further diversified by the contributions of companies like Omeros Corporation, Otsuka Pharmaceutical Co. Ltd, and Takeda Pharmaceuticals, who focus on novel treatment strategies and broaden the spectrum of available therapies. Recent entrants including Travere Therapeutics Inc, Vera Therapeutics Inc, and Vertex Pharmaceuticals Incorporated, alongside established entities like VIFOR Pharma and Visterra, highlight the dynamic competitive environment that underpins the evolving IgA Nephropathy market.
The diverse portfolio of these companies demonstrates a clear commitment to the advancement of patient care, and their ongoing research and developmental activities are poised to redefine treatment paradigms for IgA Nephropathy worldwide. Their strategic activities not only enhance clinical outcomes but also lead the charge in fostering innovation within the broader healthcare landscape.
The report delves into recent significant developments in the IgA Nephropathy Market, highlighting leading vendors and their innovative profiles. These include Alexion Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Apellis Pharmaceuticals Inc., AstraZeneca PLC, Biogen Inc., Calliditas Therapeutics AB, ChemoCentryx, Inc. by Amgen, Eledon Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, Ionis Pharmaceuticals Inc, Keymed Biosciences Inc., Merck KGaA, Novartis AG, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd, Takeda Pharmaceuticals, Travere Therapeutics Inc, Vera Therapeutics Inc, Vertex Pharmaceuticals Incorporated, VIFOR Pharma, and Visterra. Actionable Recommendations for Industry Leaders
Industry leaders are encouraged to fortify their market position by integrating strategic, evidence-based recommendations that address both short-term challenges and long-range opportunities. It is vital to invest in advanced research and development initiatives with a clear focus on enhancing diagnostic accuracy and therapeutic precision. Embracing digital health technologies, such as telemedicine and advanced data analytics platforms, can bridge the gap between clinical research and real-world patient outcomes.
Collaborative partnerships with academic institutions, biotech firms, and regulatory bodies should be prioritized to facilitate innovation and streamline drug development processes. This includes leveraging joint research initiatives to optimize treatment protocols in both clinical trial settings and everyday practice. The insights derived from detailed segmentation analyses-spanning drug classes, treatment modalities, patient demographics, end user preferences, and distribution channels-should be used to tailor therapies to local market needs while ensuring global applicability.
It is also recommended to focus on robust post-market surveillance and real-world evidence collection. This strategy not only boosts confidence in novel therapies but also creates a feedback loop that informs future research endeavors. Additionally, investing in educational programs and clinician training will further reinforce the clinical understanding and management of IgA Nephropathy.
Strategically, companies should also consider expanding their market footprint in regions that are demonstrating rapid healthcare advancements, such as Asia-Pacific, while continuing to nurture growth in traditionally strong markets like the Americas and Europe, Middle East & Africa. This balanced approach enables the capture of emerging opportunities while mitigating risks. By aligning internal innovation pipelines with evolving market dynamics, industry leaders can not only secure competitive advantages but also set new benchmarks in patient care.
In-Depth Conclusion on the IgA Nephropathy Market Trends
In conclusion, the IgA Nephropathy market is witnessing a period of profound evolution marked by cutting-edge therapeutic advancements, dynamic market segmentation, and rapidly shifting regional landscapes. The comprehensive insights detailed in this report serve to highlight the multifaceted nature of the current market environment. The confluence of technological innovations, regulatory modernization, and evolving treatment paradigms is driving the sector towards more personalized and effective care strategies.
The detailed segmentation-ranging from drug classes such as ACE inhibitors and monoclonal antibodies to varied treatment options like dialysis and immunosuppressive therapies-illuminates vital pathways for market growth. Additionally, the clear distinction between adult and pediatric patient needs, coupled with insights into diverse end-user settings and distribution channels, underscores the necessity for a tailored, strategic approach that addresses all facets of patient care.
Regional analyses further reveal that while the Americas continue to be a nexus of high-end research and clinical excellence, Europe, Middle East & Africa are embracing regulatory reforms and strategic collaborations, and Asia-Pacific is rapidly emerging as a hotbed for innovation driven by economic growth and increasing healthcare investments. The competitive landscape, shaped by industry giants and innovative newcomers alike, reinforces the importance of collaborative enterprise and agile adaptation in the face of an ever-changing market scenario.
This report not only provides a snapshot of current trends but also serves as a navigational tool for stakeholders aiming to optimize market entry strategies, operational efficiencies, and patient outcomes. As the IgA Nephropathy market continues to mature, it is imperative for industry leaders to maintain focus on research, development, and strategic partnerships to secure sustainable growth and improve the quality of life for patients worldwide.
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising prevalence of chronic kidney diseases globally
- 5.1.1.2. Increasing awareness & educational initiatives about IgA nephropathy
- 5.1.1.3. Supportive government policies and funding facilitating research
- 5.1.2. Restraints
- 5.1.2.1. High treatment costs & fragmented healthcare infrastructure
- 5.1.3. Opportunities
- 5.1.3.1. Advancements in biologic treatments for IgA nephropathy
- 5.1.3.2. Leveraging artificial intelligence to enhance clinical trials and drug discovery processes
- 5.1.4. Challenges
- 5.1.4.1. Navigating regulatory hurdles and approval timelines
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.2.1. Drug Class: Rising need for ACE inhibitors and ARBs for controlling blood pressure and reducing protein levels in urine
- 5.2.2. End User: Increasing significance of hospitals for providing quick comprehensive care for IgA nephropathy
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
- 5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
6. IgA Nephropathy Market, by Drug Class
- 6.1. Introduction
- 6.2. ACE Inhibitors
- 6.3. Angiotensin Receptor Blockers
- 6.4. Corticosteroids
- 6.5. Immunosuppressants
- 6.6. Monoclonal Antibodies
7. IgA Nephropathy Market, by Treatment
- 7.1. Introduction
- 7.2. Dialysis
- 7.3. Immunosuppressive Therapy
- 7.4. Kidney Transplant
- 7.5. Plasmapheresis
8. IgA Nephropathy Market, by Patient Type
- 8.1. Introduction
- 8.2. Adults
- 8.3. Pediatric Patients
9. IgA Nephropathy Market, by End User
- 9.1. Introduction
- 9.2. Home Healthcare
- 9.3. Hospitals
- 9.4. Research Institutes
- 9.5. Specialty Clinics
10. IgA Nephropathy Market, by Distribution Channel
- 10.1. Introduction
- 10.2. Hospital Pharmacies
- 10.3. Online Pharmacies
- 10.4. Retail Pharmacies
11. Americas IgA Nephropathy Market
- 11.1. Introduction
- 11.2. Argentina
- 11.3. Brazil
- 11.4. Canada
- 11.5. Mexico
- 11.6. United States
12. Asia-Pacific IgA Nephropathy Market
- 12.1. Introduction
- 12.2. Australia
- 12.3. China
- 12.4. India
- 12.5. Indonesia
- 12.6. Japan
- 12.7. Malaysia
- 12.8. Philippines
- 12.9. Singapore
- 12.10. South Korea
- 12.11. Taiwan
- 12.12. Thailand
- 12.13. Vietnam
13. Europe, Middle East & Africa IgA Nephropathy Market
- 13.1. Introduction
- 13.2. Denmark
- 13.3. Egypt
- 13.4. Finland
- 13.5. France
- 13.6. Germany
- 13.7. Israel
- 13.8. Italy
- 13.9. Netherlands
- 13.10. Nigeria
- 13.11. Norway
- 13.12. Poland
- 13.13. Qatar
- 13.14. Russia
- 13.15. Saudi Arabia
- 13.16. South Africa
- 13.17. Spain
- 13.18. Sweden
- 13.19. Switzerland
- 13.20. Turkey
- 13.21. United Arab Emirates
- 13.22. United Kingdom
14. Competitive Landscape
- 14.1. Market Share Analysis, 2024
- 14.2. FPNV Positioning Matrix, 2024
- 14.3. Competitive Scenario Analysis
- 14.3.1. Everest Medicines advances Asian expansion with South Korean approval of NEFECON for IgA nephropathy treatment
- 14.3.2. Novartis pioneers treatment with FDA approval of Fabhalta, an advancement for IgA nephropathy care
- 14.3.3. Novartis accelerates renal health innovation through strategic acquisition of SanReno Therapeutics for IgA nephropathy drug development
- 14.4. Strategy Analysis & Recommendation
Companies Mentioned
- 1. Alexion Pharmaceuticals, Inc.
- 2. Alnylam Pharmaceuticals, Inc.
- 3. Apellis Pharmaceuticals Inc.
- 4. AstraZeneca PLC
- 5. Biogen Inc.
- 6. Calliditas Therapeutics AB
- 7. ChemoCentryx, Inc. by Amgen
- 8. Eledon Pharmaceuticals Inc.
- 9. F. Hoffmann-La Roche Ltd
- 10. Ionis Pharmaceuticals Inc
- 11. Keymed Biosciences Inc.
- 12. Merck KGaA
- 13. Novartis AG
- 14. Omeros Corporation
- 15. Otsuka Pharmaceutical Co. Ltd
- 16. Takeda Pharmaceuticals
- 17. Travere Therapeutics Inc
- 18. Vera Therapeutics Inc
- 19. Vertex Pharmaceuticals Incorporated
- 20. VIFOR Pharma
- 21. Visterra
LIST OF FIGURES
- FIGURE 1. IGA NEPHROPATHY MARKET MULTI-CURRENCY
- FIGURE 2. IGA NEPHROPATHY MARKET MULTI-LANGUAGE
- FIGURE 3. IGA NEPHROPATHY MARKET RESEARCH PROCESS
- FIGURE 4. IGA NEPHROPATHY MARKET SIZE, 2024 VS 2030
- FIGURE 5. GLOBAL IGA NEPHROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 6. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
- FIGURE 7. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
- FIGURE 8. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
- FIGURE 9. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
- FIGURE 10. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2024 VS 2030 (%)
- FIGURE 11. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2030 (USD MILLION)
- FIGURE 12. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
- FIGURE 13. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
- FIGURE 14. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
- FIGURE 15. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
- FIGURE 16. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
- FIGURE 17. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
- FIGURE 18. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
- FIGURE 19. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
- FIGURE 20. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
- FIGURE 21. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
- FIGURE 22. ASIA-PACIFIC IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
- FIGURE 23. ASIA-PACIFIC IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
- FIGURE 24. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
- FIGURE 25. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
- FIGURE 26. IGA NEPHROPATHY MARKET SHARE, BY KEY PLAYER, 2024
- FIGURE 27. IGA NEPHROPATHY MARKET, FPNV POSITIONING MATRIX, 2024
LIST OF TABLES
- TABLE 1. IGA NEPHROPATHY MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
- TABLE 3. GLOBAL IGA NEPHROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 6. IGA NEPHROPATHY MARKET DYNAMICS
- TABLE 7. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 8. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 11. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 13. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 14. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 15. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 16. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY KIDNEY TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 18. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 19. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 20. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 21. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 22. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 23. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 24. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 25. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 26. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 27. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 28. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 29. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 30. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 31. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 32. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 33. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 34. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 35. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 36. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 37. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 38. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 39. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 40. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 41. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 42. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 43. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 44. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 45. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 46. CANADA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 47. CANADA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 48. CANADA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 49. CANADA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 50. CANADA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 51. MEXICO IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 52. MEXICO IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 53. MEXICO IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 54. MEXICO IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 55. MEXICO IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 56. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 57. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 58. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 59. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 60. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 61. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 62. ASIA-PACIFIC IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 63. ASIA-PACIFIC IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 64. ASIA-PACIFIC IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 65. ASIA-PACIFIC IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 66. ASIA-PACIFIC IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 67. ASIA-PACIFIC IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 68. AUSTRALIA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 69. AUSTRALIA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 70. AUSTRALIA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 71. AUSTRALIA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 72. AUSTRALIA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 73. CHINA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 74. CHINA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 75. CHINA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 76. CHINA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 77. CHINA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 78. INDIA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 79. INDIA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 80. INDIA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 81. INDIA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 82. INDIA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 83. INDONESIA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 84. INDONESIA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 85. INDONESIA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 86. INDONESIA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 87. INDONESIA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 88. JAPAN IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 89. JAPAN IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 90. JAPAN IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 91. JAPAN IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 92. JAPAN IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 93. MALAYSIA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 94. MALAYSIA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 95. MALAYSIA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 96. MALAYSIA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 97. MALAYSIA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 98. PHILIPPINES IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 99. PHILIPPINES IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 100. PHILIPPINES IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 101. PHILIPPINES IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 102. PHILIPPINES IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 103. SINGAPORE IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 104. SINGAPORE IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 105. SINGAPORE IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 106. SINGAPORE IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 107. SINGAPORE IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 108. SOUTH KOREA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 109. SOUTH KOREA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 110. SOUTH KOREA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 111. SOUTH KOREA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 112. SOUTH KOREA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 113. TAIWAN IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 114. TAIWAN IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 115. TAIWAN IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 116. TAIWAN IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 117. TAIWAN IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 118. THAILAND IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 119. THAILAND IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 120. THAILAND IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 121. THAILAND IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 122. THAILAND IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 123. VIETNAM IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 124. VIETNAM IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 125. VIETNAM IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 126. VIETNAM IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 127. VIETNAM IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 128. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 129. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 130. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 131. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 132. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 133. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 134. DENMARK IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 135. DENMARK IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 136. DENMARK IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 137. DENMARK IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 138. DENMARK IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 139. EGYPT IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 140. EGYPT IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 141. EGYPT IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 142. EGYPT IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 143. EGYPT IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 144. FINLAND IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 145. FINLAND IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 146. FINLAND IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 147. FINLAND IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 148. FINLAND IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 149. FRANCE IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 150. FRANCE IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 151. FRANCE IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 152. FRANCE IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 153. FRANCE IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 154. GERMANY IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 155. GERMANY IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 156. GERMANY IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 157. GERMANY IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 158. GERMANY IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 159. ISRAEL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 160. ISRAEL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 161. ISRAEL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 162. ISRAEL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 163. ISRAEL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 164. ITALY IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 165. ITALY IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 166. ITALY IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 167. ITALY IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 168. ITALY IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 169. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 170. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 171. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 172. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 173. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 174. NIGERIA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 175. NIGERIA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 176. NIGERIA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 177. NIGERIA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 178. NIGERIA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 179. NORWAY IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 180. NORWAY IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 181. NORWAY IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 182. NORWAY IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 183. NORWAY IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 184. POLAND IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 185. POLAND IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 186. POLAND IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 187. POLAND IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 188. POLAND IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 189. QATAR IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 190. QATAR IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 191. QATAR IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 192. QATAR IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 193. QATAR IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 194. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 195. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 196. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 197. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 198. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 199. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 200. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 201. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 202. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 203. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 204. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 205. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 206. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 207. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 208. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 209. SPAIN IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 210. SPAIN IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 211. SPAIN IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 212. SPAIN IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 213. SPAIN IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 214. SWEDEN IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 215. SWEDEN IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 216. SWEDEN IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 217. SWEDEN IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 218. SWEDEN IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 219. SWITZERLAND IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 220. SWITZERLAND IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 221. SWITZERLAND IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 222. SWITZERLAND IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 223. SWITZERLAND IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 224. TURKEY IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 225. TURKEY IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 226. TURKEY IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 227. TURKEY IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 228. TURKEY IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 229. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 230. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 231. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 232. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 233. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 234. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 235. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 236. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
- TABLE 237. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
- TABLE 238. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 239. IGA NEPHROPATHY MARKET SHARE, BY KEY PLAYER, 2024
- TABLE 240. IGA NEPHROPATHY MARKET, FPNV POSITIONING MATRIX, 2024
